Table 1.
Characteristics of DCCT/EDIC male participants at EDIC year 17 (N=635) by ED and LUTS status
| No LUTS or ED N=284 | ED only N=193 | LUTS only N=61 | ED & LUTS N=97 | p-value | |
|---|---|---|---|---|---|
| Sociodemographic/Clinical | |||||
| Attained Age (years) | 49·3±6·3 | 52·9±6·2 | 51·4±6·7 | 55·7±5·7 | <0·0001 |
| Married | 217 (77) | 139 (72) | 45 (76) | 76 (80) | 0·5 |
| Current Cigarette Smoker | 25 (9) | 26 (14) | 5 (8) | 17 (18) | 0·07 |
| Current Drinker | 136 (48) | 103 (54) | 40 (68) | 44 (46) | 0·03 |
| Body Mass Index (BMI) (kg/m2) | 28·5±4·4 | 29·5±5·0 | 28·2±3·6 | 28·9±5·6 | 0·08 |
| BMI Category (kg/m2) | |||||
| Normal (BMI<25) | 63 (23) | 32 (17) | 11 (19) | 26 (28) | 0·1 |
| Overweight (25≤BMI<30) | 124 (44) | 76 (40) | 30 (52) | 34 (37) | |
| Obese (BMI≥30) | 92 (33) | 82 (43) | 17 (29) | 33 (35) | |
| Total Testosterone (ng/dL) | 553·3±196·0 | 538·8±238·4 | 548·8±208·8 | 546·1±202·4 | 0·6 |
| Diabetes Control and Treatment | |||||
| Primary Prevention Cohort | 149 (52) | 87 (45) | 37 (61) | 42 (43) | 0·07 |
| Intensive Treatment Group | 144 (51) | 96 (50) | 29 (48) | 46 (47) | 0·9 |
| Duration of diabetes (years) | 29·4±4·9 | 29·6±4·5 | 28·4±4·7 | 30·4±5·2 | 0·06 |
| DCCT/EDIC time-weighted HbA1c (%) | 7·8±0·9 | 8·2±1·0 | 7·8±1·0 | 8·1±1·0 | 0·0001 |
| DCCT/EDIC time-weighted HbA1c (mmol/mol) | 62±10 | 66±11 | 62±11 | 65±11 | |
| Diabetic Complications | |||||
| Retinopathy* | 44 (15) | 45 (23) | 12 (20) | 25 (26) | 0·07 |
| Nephropathy** | |||||
| None (AER<30) | 236 (86) | 134 (72) | 43 (74) | 55 (61) | <0·0001 |
| Microalbuminuria (30≤AER<300) | 29 (11) | 39 (21) | 6 (10) | 28 (31) | |
| Albuminuria (AER≥300) | 10 (4) | 14 (7) | 9 (16) | 7 (8) | |
| eGFR<60 | 5 (2) | 15 (8) | 3 (5) | 4 (4) | 0·02 |
| Blood Pressure Control | |||||
| DCCT/EDIC time-weighted SBP (mmHg) | 119·4±7·4 | 122·0±6·9 | 121·2±7·0 | 122·2±8·5 | 0·0002 |
| DCCT/EDIC time-weighted DBP (mmHg) | 75·9±4·8 | 76·6±4·4 | 76·0±5·0 | 75·0±4·7 | 0·1 |
| Hypertension# | 181 (64) | 145 (76) | 38 (64) | 73 (77) | 0·02 |
| Antihypertensive Use§ | |||||
| Beta-blockers | 21 (7) | 30 (16) | 2 (3) | 18 (19) | 0·0007 |
| ACE inhibitors or ARB blockers | 155 (55) | 131 (68) | 32 (54) | 66 (69) | 0·005 |
| Ca-channel blockers | 15 (5) | 21 (11) | 6 (10) | 13 (14) | 0·04 |
Data are Mean±Std or N (%). P-values based the Kruskal-Wallis test for quantitative variables or the Contingency chi-square for qualitative variables.
Sample sizes may vary due to missing data.
Retinopathy defined through EDIC year 14 using the Early Treatment Diabetic Retinopathy Study on a scale of 0–23 (<12 Non Proliferative or None, ≥12 Proliferative).
AER= AER=Albumin Excretion Rate (mg/24hr) at EDIC year 17/18. Estimated GFR (eGFR) at EDIC year 16 using the CKD-EPI equation.
Hypertension defined as sitting systolic blood pressure (SBP) ≥140 mmHg and/or diastolic blood pressure (DBP)≥90 mmHg or the use of antihypertensive medication.
ACE=Angiotensin-converting enzyme; ARB=Angiotensin receptor blockers.